News

Public · Published

Truist Securities maintains HCA Healthcare at Buy, raises price target to $510 from $495

Truist Securities maintained a Buy rating on HCA Healthcare and raised its price target to $510 from $495, a 3.0% increase. The new target implies 9.0% upside from the November 2 close of $467.73.

Published:

Updated:

What happened

Truist Securities maintained a Buy rating on HCA Healthcare and raised its price target to $510 from $495, a 3.0% increase. The new target implies 9.0% upside from the November 2 close of $467.73.

Confirmed

Global impact / market context

A higher price target signals that Truist expects more share price upside, which can draw investor attention to HCA. The 9.0% implied gain suggests the analyst sees room for the stock to rise from its recent close.

Analyst inference

Recent analyst targets on HCA range from $401 to $521, with ratings spanning Equal-Weight to Buy and Overweight. Truist's $510 target sits near the high end but below the $521 target, suggesting mostly positive analyst views with some caution.

Analyst inference

What to watch

  1. Watch whether HCA trades toward Truist's $510 target or stays near the $467.73 November 2 close, a gap Truist frames as 9.0% upside. Confirmed
  2. Watch for new analyst notes on HCA and whether other firms raise targets, since the current range of $401 to $521 shows differing views on upside. Proposed
  3. Watch HCA's next financial results and guidance for signs that support the higher target, since analyst targets often depend on expected profit and revenue trends. Analyst inference

Evidence

  • Original source link unavailable